Therapy Development
This category covers scientific and strategic topics in antibody therapy development, from early-stage candidate selection to scalable biologics manufacturing. Supporting teams that work with a dedicated therapeutics development partner or a full-service recombinant antibody production service.
Articles about Therapy Development (5)
-
Speed vs. Quality in Early Drug Development: Striking the Right Balance for Antibody Therapeutics
In drug development, speed without reproducibility risks costly setbacks. This article shows how high-quality antibody materials, early testing, and smart design enable faster, more reliable programs without compromising rigor.
-
Why Promising Antibody Candidates Fail Before Clinical Trials – and How to Avoid It
Despite strong market growth, most antibody candidates fail early due to developability, pharmacokinetics, or immunogenicity issues. This article outlines key risks and strategies to de-risk development and speed the path from discovery to IND.
-
Fast-Tracking Bispecific Antibody Development: What Can Go Wrong?
Bispecific antibodies hold great promise, but rushing development can trigger design and manufacturing risks. This article explores how smart strategies and expert partnerships accelerate bsAb programs without compromising quality.
-
The Risks of Over-Promising in Early-Stage Biologics Development
In early biologics development, over-promising can derail programs and erode trust. This article explores the causes, consequences, and how data-driven planning safeguards progress and credibility.
-
The Stability Problem: Why Some Recombinant Antibodies Don’t Make It to Market
Stability is key to antibody success, but physical, chemical, and biological issues often derail candidates. This article covers causes, consequences, and strategies to improve stability, manufacturability, and speed development to market.